RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2022-11, Vol.18 (6), p.2140533 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 2140533 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 18 |
| creator | Packnett, Elizabeth R. Winer, Isabelle H. Larkin, Heather Oladapo, Abiola Gonzales, Tara Wojdyla, Matthew Goldstein, Mitchell Smith, Vincent C. |
| description | Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions and those born at |
| doi_str_mv | 10.1080/21645515.2022.2140533 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_21645515_2022_2140533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6b66e6d3a8c14c57a799f9529b689f38</doaj_id><sourcerecordid>2739066397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-11d6e365d72880be71a5df16b192c275f7556e5dc8fb88063a54e95fe9ef88a53</originalsourceid><addsrcrecordid>eNp9UU1v1DAQjRCIVqU_AeRjOWTxR8aJEUJUFZRKlZD4EjfLScatqyQOttNq--vxstsVveCLPTPvvXnyK4qXjK4YbegbzmQFwGDFKecrzioKQjwpDjf9EqD69XT_ZnBQHMd4Q_OpKa-kfF4cCFkxzkEcFv7rt59lwMEk7Mm1j7NLZnD3Jjk_ETP1xC9pzhVOicx5cuvul9G0ZIlI3ERuMazJHDBhGMlJ60MmJfKOK3J3fvo6I6yZUnxLOKWizGbpi-KZNUPE4919VPz49PH72efy8sv5xdnpZdmBqFLJWC9RSOhr3jS0xZoZ6C2TLVO84zXYGkAi9F1j2wyQwkCFCiwqtE1jQBwVF1vd3psbPQc3mrDW3jj9t-HDlTYhuW5ALVspUfbCNB2rOqhNrZRVwFUrG2VFk7Xeb7XmpR2x7_JfBDM8En08mdy1vvK3WtWVFM3GzMlOIPjfC8akRxc7HAYzoV-i5rVQVEqh6gyFLbQLPsaAdr-GUb3JXj9krzfZ6132mffqX4971kPSGfBhC8iZ-DCaOx-GXiezHnywwUydi1r8f8cfdom8aw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2739066397</pqid></control><display><type>article</type><title>RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Packnett, Elizabeth R. ; Winer, Isabelle H. ; Larkin, Heather ; Oladapo, Abiola ; Gonzales, Tara ; Wojdyla, Matthew ; Goldstein, Mitchell ; Smith, Vincent C.</creator><creatorcontrib>Packnett, Elizabeth R. ; Winer, Isabelle H. ; Larkin, Heather ; Oladapo, Abiola ; Gonzales, Tara ; Wojdyla, Matthew ; Goldstein, Mitchell ; Smith, Vincent C.</creatorcontrib><description>Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions and those born at <35 weeks gestational age (wGA). This study compared RSV-related hospitalization (RSVH) and RSVH characteristics in very preterm (<29 wGA) and term (>37 wGA) infants. Using the MarketScan Commercial and Multi-State Medicaid administrative claims databases, infants born between 7/1/2003 and 6/30/2020 were identified and classified as very preterm or term. Infants with evidence of health conditions, such as congenital heart disease and cystic fibrosis, were excluded. During 2003-2020 RSV seasons (November to March), claims incurred by infants while they were <12 months old were evaluated for outpatient administration of palivizumab and RSVH. The study included 40,123 very preterm infants and 4,421,942 term infants. Rate of RSVH in very preterm infants ranged 1.5-3.8 per 100 infant-seasons in commercially insured infants and 3.5-8.4 in Medicaid insured infants and were inversely related to wGA at birth. Relative risk of RSVH in very preterm was 3-4 times higher, and ICU admissions and mechanical ventilation were more common during RSVH in very preterm infants relative to term infants. However, these outcomes were less common or less severe in very preterm infants who received outpatient palivizumab administration, despite evidence of higher baseline risk of RSVH in these infants.</description><identifier>ISSN: 2164-5515</identifier><identifier>ISSN: 2164-554X</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2022.2140533</identifier><identifier>PMID: 36412253</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Antiviral Agents - therapeutic use ; Child ; Gestational Age ; Hospitalization ; Humans ; Immunotherapeutics ; Infant ; Infant, Newborn ; Infant, Premature ; Infant, Premature, Diseases - prevention & control ; Palivizumab - therapeutic use ; pediatric hospitalization ; pre-exposure prophylaxis ; premature ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - epidemiology ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Syncytial Virus, Human ; respiratory tract infections ; United States - epidemiology</subject><ispartof>Human vaccines & immunotherapeutics, 2022-11, Vol.18 (6), p.2140533</ispartof><rights>2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022</rights><rights>2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-11d6e365d72880be71a5df16b192c275f7556e5dc8fb88063a54e95fe9ef88a53</citedby><cites>FETCH-LOGICAL-c534t-11d6e365d72880be71a5df16b192c275f7556e5dc8fb88063a54e95fe9ef88a53</cites><orcidid>0000-0002-4731-6956</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746385/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746385/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36412253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Packnett, Elizabeth R.</creatorcontrib><creatorcontrib>Winer, Isabelle H.</creatorcontrib><creatorcontrib>Larkin, Heather</creatorcontrib><creatorcontrib>Oladapo, Abiola</creatorcontrib><creatorcontrib>Gonzales, Tara</creatorcontrib><creatorcontrib>Wojdyla, Matthew</creatorcontrib><creatorcontrib>Goldstein, Mitchell</creatorcontrib><creatorcontrib>Smith, Vincent C.</creatorcontrib><title>RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions and those born at <35 weeks gestational age (wGA). This study compared RSV-related hospitalization (RSVH) and RSVH characteristics in very preterm (<29 wGA) and term (>37 wGA) infants. Using the MarketScan Commercial and Multi-State Medicaid administrative claims databases, infants born between 7/1/2003 and 6/30/2020 were identified and classified as very preterm or term. Infants with evidence of health conditions, such as congenital heart disease and cystic fibrosis, were excluded. During 2003-2020 RSV seasons (November to March), claims incurred by infants while they were <12 months old were evaluated for outpatient administration of palivizumab and RSVH. The study included 40,123 very preterm infants and 4,421,942 term infants. Rate of RSVH in very preterm infants ranged 1.5-3.8 per 100 infant-seasons in commercially insured infants and 3.5-8.4 in Medicaid insured infants and were inversely related to wGA at birth. Relative risk of RSVH in very preterm was 3-4 times higher, and ICU admissions and mechanical ventilation were more common during RSVH in very preterm infants relative to term infants. However, these outcomes were less common or less severe in very preterm infants who received outpatient palivizumab administration, despite evidence of higher baseline risk of RSVH in these infants.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Child</subject><subject>Gestational Age</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immunotherapeutics</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infant, Premature</subject><subject>Infant, Premature, Diseases - prevention & control</subject><subject>Palivizumab - therapeutic use</subject><subject>pediatric hospitalization</subject><subject>pre-exposure prophylaxis</subject><subject>premature</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - epidemiology</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory Syncytial Virus, Human</subject><subject>respiratory tract infections</subject><subject>United States - epidemiology</subject><issn>2164-5515</issn><issn>2164-554X</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9UU1v1DAQjRCIVqU_AeRjOWTxR8aJEUJUFZRKlZD4EjfLScatqyQOttNq--vxstsVveCLPTPvvXnyK4qXjK4YbegbzmQFwGDFKecrzioKQjwpDjf9EqD69XT_ZnBQHMd4Q_OpKa-kfF4cCFkxzkEcFv7rt59lwMEk7Mm1j7NLZnD3Jjk_ETP1xC9pzhVOicx5cuvul9G0ZIlI3ERuMazJHDBhGMlJ60MmJfKOK3J3fvo6I6yZUnxLOKWizGbpi-KZNUPE4919VPz49PH72efy8sv5xdnpZdmBqFLJWC9RSOhr3jS0xZoZ6C2TLVO84zXYGkAi9F1j2wyQwkCFCiwqtE1jQBwVF1vd3psbPQc3mrDW3jj9t-HDlTYhuW5ALVspUfbCNB2rOqhNrZRVwFUrG2VFk7Xeb7XmpR2x7_JfBDM8En08mdy1vvK3WtWVFM3GzMlOIPjfC8akRxc7HAYzoV-i5rVQVEqh6gyFLbQLPsaAdr-GUb3JXj9krzfZ6132mffqX4971kPSGfBhC8iZ-DCaOx-GXiezHnywwUydi1r8f8cfdom8aw</recordid><startdate>20221130</startdate><enddate>20221130</enddate><creator>Packnett, Elizabeth R.</creator><creator>Winer, Isabelle H.</creator><creator>Larkin, Heather</creator><creator>Oladapo, Abiola</creator><creator>Gonzales, Tara</creator><creator>Wojdyla, Matthew</creator><creator>Goldstein, Mitchell</creator><creator>Smith, Vincent C.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4731-6956</orcidid></search><sort><creationdate>20221130</creationdate><title>RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020</title><author>Packnett, Elizabeth R. ; Winer, Isabelle H. ; Larkin, Heather ; Oladapo, Abiola ; Gonzales, Tara ; Wojdyla, Matthew ; Goldstein, Mitchell ; Smith, Vincent C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-11d6e365d72880be71a5df16b192c275f7556e5dc8fb88063a54e95fe9ef88a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Child</topic><topic>Gestational Age</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immunotherapeutics</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infant, Premature</topic><topic>Infant, Premature, Diseases - prevention & control</topic><topic>Palivizumab - therapeutic use</topic><topic>pediatric hospitalization</topic><topic>pre-exposure prophylaxis</topic><topic>premature</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - epidemiology</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory Syncytial Virus, Human</topic><topic>respiratory tract infections</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Packnett, Elizabeth R.</creatorcontrib><creatorcontrib>Winer, Isabelle H.</creatorcontrib><creatorcontrib>Larkin, Heather</creatorcontrib><creatorcontrib>Oladapo, Abiola</creatorcontrib><creatorcontrib>Gonzales, Tara</creatorcontrib><creatorcontrib>Wojdyla, Matthew</creatorcontrib><creatorcontrib>Goldstein, Mitchell</creatorcontrib><creatorcontrib>Smith, Vincent C.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Packnett, Elizabeth R.</au><au>Winer, Isabelle H.</au><au>Larkin, Heather</au><au>Oladapo, Abiola</au><au>Gonzales, Tara</au><au>Wojdyla, Matthew</au><au>Goldstein, Mitchell</au><au>Smith, Vincent C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2022-11-30</date><risdate>2022</risdate><volume>18</volume><issue>6</issue><spage>2140533</spage><pages>2140533-</pages><issn>2164-5515</issn><issn>2164-554X</issn><eissn>2164-554X</eissn><abstract>Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions and those born at <35 weeks gestational age (wGA). This study compared RSV-related hospitalization (RSVH) and RSVH characteristics in very preterm (<29 wGA) and term (>37 wGA) infants. Using the MarketScan Commercial and Multi-State Medicaid administrative claims databases, infants born between 7/1/2003 and 6/30/2020 were identified and classified as very preterm or term. Infants with evidence of health conditions, such as congenital heart disease and cystic fibrosis, were excluded. During 2003-2020 RSV seasons (November to March), claims incurred by infants while they were <12 months old were evaluated for outpatient administration of palivizumab and RSVH. The study included 40,123 very preterm infants and 4,421,942 term infants. Rate of RSVH in very preterm infants ranged 1.5-3.8 per 100 infant-seasons in commercially insured infants and 3.5-8.4 in Medicaid insured infants and were inversely related to wGA at birth. Relative risk of RSVH in very preterm was 3-4 times higher, and ICU admissions and mechanical ventilation were more common during RSVH in very preterm infants relative to term infants. However, these outcomes were less common or less severe in very preterm infants who received outpatient palivizumab administration, despite evidence of higher baseline risk of RSVH in these infants.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>36412253</pmid><doi>10.1080/21645515.2022.2140533</doi><orcidid>https://orcid.org/0000-0002-4731-6956</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2022-11, Vol.18 (6), p.2140533 |
| issn | 2164-5515 2164-554X 2164-554X |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_21645515_2022_2140533 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antiviral Agents - therapeutic use Child Gestational Age Hospitalization Humans Immunotherapeutics Infant Infant, Newborn Infant, Premature Infant, Premature, Diseases - prevention & control Palivizumab - therapeutic use pediatric hospitalization pre-exposure prophylaxis premature Respiratory syncytial virus Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus, Human respiratory tract infections United States - epidemiology |
| title | RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A38%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RSV-related%20hospitalization%20and%20outpatient%20palivizumab%20use%20in%20very%20preterm%20(born%20at%20%3C29%20wGA)%20infants:%202003-2020&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Packnett,%20Elizabeth%20R.&rft.date=2022-11-30&rft.volume=18&rft.issue=6&rft.spage=2140533&rft.pages=2140533-&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2022.2140533&rft_dat=%3Cproquest_cross%3E2739066397%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2739066397&rft_id=info:pmid/36412253&rft_doaj_id=oai_doaj_org_article_6b66e6d3a8c14c57a799f9529b689f38&rfr_iscdi=true |